Alfa Aesar issues new biomedical technologies brochure

Published: 16-Oct-2013
Research & Development Pharmaceutical

Features the Biomedical Technologies line of cell research products

With the recent acquisition of Biomedical Technologies (BTI), Alfa Aesar is pleased to offer a new brochure featuring the BTI line of cell research products.

BTI has been manufacturing life science research products for more than 30 years, with a commitment to its customers of technology, quality and value. The product line features cell culture products, cell growth factors, lipoproteins, modified lipoproteins (Ox-LDL, Ac-LDL, c-LDL), immunoassay kits and compounds, antibodies & proteins, biochemical products.

Alfa Aesar will continue to build upon the BTI product range as it expands its portfolio of unique biochemical products for the researcher.

Request literature

  • Companies:
  • Thermo Fisher Scientific
See more

You may also like

Research & Development

Verici DX reaches global licensing and commercialisation agreement with Thermo Fisher Scientific

Read more
Agreement grants rights to further develop an assay for pretransplant prognostic testing

Trending Articles

  1. Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222 Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the vaccine candidate drug substance commencing late in the third quarter of 2020
  2. ACG awarded ‘Great Place To Work’ certification for a fourth consecutive year The award recognises employers that create an outstanding experience for employees
  3. Building strong foundations for a resilient and planet-friendly future Having recently released its inaugural environmental, social and governance (ESG) report, Dr Kevin Robinson caught up with Gigi Bat-Erdene, Global ESG Program Manager at PCI Pharma Services, to find out how this leading CDMO is tackling climate science, workforce empowerment, responsible waste management and supply chain security
  4. Rapid increase in purchasing teams expected at CPHI North America Macro-uncertainty and large CDMO acquisitions attributed to have driven a surge in R&D, purchasing and QC/QA attendees at event
  5. Wacker Chemical Corporation promotes Christoph Kowitz to President of US subsidiary The position originally held by David Willhoit is a promotion from Christoph's six year tenure as the Head of Corporate R&D

Upcoming event

Making Pharmaceuticals

23–24 April 2024 | Exhibition | Coventry, UK See all

You may also like

Research & Development

Verici DX reaches global licensing and commercialisation agreement with Thermo Fisher Scientific

Agreement grants rights to further develop an assay for pretransplant prognostic testing
Manufacturing

Multiply Labs' robotic pharmaceutical manufacturing project reaches proof-of-concept

The consortium which contains Multiply Labs, Thermo Fisher, Cytiva, UCSF and Charles River has reached proof-of-concept on a robotic and automated cell manufacturing system
Drug Delivery

Taking a decentralised approach to commercialising cell and gene therapies

With the medical world facing some of the worst cancer drug shortages in history, many thousands of patients are not getting the treatments they need. To overcome these challenges, fundamental changes are required in terms of cell therapy process development and manufacturing work flows. Dr Kevin Robinson (KSR) spoke to Evan Zynda, Senior Staff Scientist at Thermo Fisher Scientific, to find out more
Manufacturing

Thermo Fisher: Microplastic-free beads for research

Invitrogen DynaGreen Magnetic Beads enable researchers to reduce their environmental impact during protein purification
Research & Development

Thermo Fisher Scientific recognises Tandem Mass Tag Grant Award winners

International competition rewards top proteomics researchers for outstanding innovation and societal impact
Research & Development

Thermo Fisher introduces updated genetic analyser

The mid-throughput genetic analyser introduces design and technological improvements for flexibility, usability and connectivity
Analysis

Moving forward with N-nitrosamine analysis

The June 2018 discovery of N-nitrosodimethylamine (NDMA) in the active pharmaceutical ingredient (API) of valsartan led to unprecedented activity by health authorities and the pharmaceutical industry to understand the root causes and mitigate the presence of these potentially carcinogenic impurities in pharmaceutical products<sup>1,2</sup>
Subscribe now